In this review, we focus on the significance of PPARγ activity regulation (PTMs and SPPARMs) in the occurrence, development and treatment of atherosclerotic diseases, and further clarifies the value of PPARγ as a therapeutic target for anti-atherosclerosis. This evidence concerns the gene PPARG and atherosclerosis.